Caseys CASY Q1 2026 Earnings Why the Beat Matters Veea VEEA Flat at 052 Consolidation Continues 20260514 Elutia ELUT Gains 680 Support Holds at 104 20260518 Varonis Systems VRNS Gained 268 Can It Break 3103 20260519 Berkshire Hathaway Portfolio Revamp Delta Air Lines and Alphabet Positions Revealed Endurance Technologies IPO Opens Company Targets Rs 1162 Crore Through Stake Dilution Weekly Survey Highlights Importance of Rate Shopping for Mortgage Borrowers Donald Trump JrBacked Enhanced Games Set for Sunday Debut with Broader Expansion Plans Photronics The Unheralded Semiconductor Stock Quietly Delivering 17 Annual Returns Pokmon Card Boom Nostalgia Speculation and HighProfile Collectors Drive MultiMillion Dollar Market IDT Q1 2026 Earnings Earnings Miss Estimates Despite Positive Stock Movement NXTC Q1 2026 Earnings SmallerthanExpected Loss but Stock Plunges 22 as Revenue Stays at Zero Intellia Therapeutics NTLA Q1 2026 Earnings NarrowerThanExpected Loss Fuels Market Optimism Four Seasons Education FEDU Q4 2019 Earnings Significant EPS Miss Drives Stock Decline NetEase NTES Q1 2026 Earnings Strong EPS Beat Drives Positive Market Reaction BWB Q1 2026 Earnings EPS Slightly Misses Estimates Stock Edges Lower Select Water Solutions WTTR Retreats 248 Testing Key Support Levels Near 18 Apple Inc AAPL Hovers Near Flatline Amid Key Support and Resistance Levels Magyar Bancorp Inc MGYR Edges Lower as Resistance Caps NearTerm Upside SR Bancorp Inc SRBK Navigates Modest Decline Amid Consolidation Near Support Levels TG Therapeutics TGTX Slips Modestly as Stock Consolidates Near Key Support Levels JAKK Q1 2026 Earnings EPS Surprises Positive but Revenue Details Absent Stock Dips GHC Q1 2026 Earnings EPS Surges Past Estimates by 268 Revvity Inc RVTY Q1 2026 Earnings EPS Beat Amid Revenue Discretion Shares Edge Higher CLLS Q1 2026 Earnings Narrowing Losses as Cost Discipline Surprises to the Upside DPRO Q1 2026 Earnings EPS Misses Estimates Narrowly Stock Surges 1387 Oura Health Tech Files Confidentially for IPO Plans Public Debut Kalaris Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Highlights Cost Discipline Amid PreRevenue Biotech RELX RELX Edges Lower Near 3285 as Shares Consolidate Between Key Levels